CoChat
Sign Up
Cited by 42

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Methods and novel technology for microRNA quantification in colorectal cancer screening

Moody, Laura, He, Hongshan, Pan, Yuan-Xiang, Chen, Hong·2017·Clinical Epigenetics
DOI 10.1186/s13148-017-0420-9PMC PMC5655825
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13148-017-0420-9

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 145

  1. Siegel RL, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93. · DOI
  2. Bretthauer M. Colorectal cancer screening. J Intern Med. 2011;270(2):87–98. · DOI
  3. Dekker E, van Gulik T. Colorectal cancer: what the clinician wants to know. Cancer Imaging. 2005;5 Spec No A:S127–32. · DOI
  4. Lin JS, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2016;315(23):2576–94. · DOI
  5. Baxter NN, et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol. 2012;30(21):2664–9. · DOI
  6. Kahi CJ, Anderson JC, Rex DK. Screening and surveillance for colorectal cancer: state of the art. Gastrointest Endosc. 2013;77(3):335–50. · DOI
  7. Baxter NN, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150(1):1–8. · DOI
  8. Walleser S, et al. What is the value of computered tomography colonography in patients screening positive for fecal occult blood? A systematic review and economic evaluation. Clin Gastroenterol Hepatol. 2007;5(12):1439–46. quiz 1368 · DOI
  9. Sung JJ, et al. Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology. 2003;124(3):608–14. · DOI
  10. Graser A, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut. 2009;58(2):241–8. · DOI
  11. Neugut AI, Lebwohl B. Colonoscopy vs sigmoidoscopy screening: getting it right. JAMA. 2010;304(4):461–2. · DOI
  12. Segnan N, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial—SCORE. J Natl Cancer Inst. 2011;103(17):1310–22. · DOI
  13. Atkin WS, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624–33. · DOI
  14. Yeazel MW, et al. Colorectal cancer screening adherence in a general population. Cancer Epidemiol Biomark Prev. 2004;13(4):654–7. · DOI
  15. Subramanian S, et al. Adherence with colorectal cancer screening guidelines: a review. Prev Med. 2004;38(5):536–50. · DOI
  16. Narula N, et al. Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart review. Can J Gastroenterol Hepatol. 2014;28(8):421–6. · DOI
  17. Levin B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570–95. · DOI
  18. Malila N, et al. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ. 2008;337:a2261. · DOI
  19. Elsafi SH, et al. The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings. Clin Exp Gastroenterol. 2015;8:279–84. · DOI
  20. Whitlock EP, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9):638–58. · DOI
  21. Katsoula A, et al. Diagnostic accuracy of fecal immunochemical test in patients at increased risk for colorectal cancer: a meta-analysis. JAMA Intern Med. 2017;177(8):1110-1118. doi: 10.1001/jamainternmed.2017.2309 . PubMed PMID: 28628706. · DOI
  22. Heigh RI, et al. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PLoS One. 2014;9(1):e85659. · DOI · Paper page
  23. Lidgard GP, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013;11(10):1313–8. · DOI · Paper page
  24. Duffy MJ, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348–60. · DOI
  25. Duffy MJ, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39(6):718–27. · DOI
  26. Thomas DS, et al. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer. 2015;113(2):268–74. · DOI
  27. Filiz AI, et al. Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients—is it important? Clinics (Sao Paulo). 2009;64(4):287–94. · DOI
  28. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47(4):624–30. · DOI
  29. Su BB, Shi H, Wan J. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol. 2012;18(17):2121–6. · DOI
  30. Panel., F.a.D.A.M.a.C.G. FDA executive summary: epigenomics AG Epi proColon. 2014.
  31. Yan S, et al. Diagnostic value of methylated septin9 for colorectal cancer screening: a meta-analysis. Med Sci Monit. 2016;22:3409–18. · DOI
  32. van Rooij, E. and E.N. Olson, MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov, 2012. 11(11): p. 860-872. · DOI
  33. Wang QX, et al. Altered MiRNA expression in gastric cancer: a systematic review and meta-analysis. Cell Physiol Biochem. 2015;35(3):933–44. · DOI
  34. Tilghman SL, et al. Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer. J Health Care Poor Underserved. 2013;24(1 Suppl):36–46. · DOI
  35. Lodewijk L, et al. The value of miRNA in diagnosing thyroid cancer: a systematic review. Cancer Biomark. 2012;11(6):229–38. · DOI
  36. Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One. 2012;7(11):e50966. · DOI
  37. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110(3):483–95. · DOI
  38. Larrea E, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci. 2016;17(5):627. · DOI
  39. Wahl P, et al. Acute effects of different exercise protocols on the circulating vascular microRNAs -16, -21, and -126 in trained subjects. Front Physiol. 2016;7:643. · DOI
  40. Hsieh CH, et al. Weight-reduction through a low-fat diet causes differential expression of circulating microRNAs in obese C57BL/6 mice. BMC Genomics. 2015;16:699. · DOI
  41. Ajit SK. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel). 2012;12(3):3359–69. · DOI
  42. Song MY, et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One. 2012;7(3):e33608. · DOI
  43. Brase JC, et al. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;9:306. · DOI
  44. Chen WY, et al. The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer. Int J Clin Exp Pathol. 2015;8(6):7092–101.
  45. Li LP, et al. The diagnostic efficacy and biological effects of microRNA-29b for colon cancer. Technol Cancer Res Treat. 2016;15(6):772–9. · DOI
  46. Lv ZC, et al. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumor Biol. 2015;36(3):1619–25. · DOI
  47. Ng L, et al. Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer. Oncotarget. 2017;8(16):27393–400. · DOI
  48. Nonaka R, et al. Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Oncol Rep. 2014;32(6):2354–8. · DOI
  49. Pu XX, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25(10):1674–80. · DOI
  50. Shan LQ, et al. Diagnostic value of circulating miR-21 for colorectal cancer: a meta-analysis. Cancer Biomarkers. 2015;15(1):47–56. · DOI
  51. Wang W, et al. Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer. Eur J Cancer Care (Engl). 2017;26(4):e12448. · DOI
  52. Xu CJ, Gu L. The diagnostic effect of serum miR-196b as biomarker in colorectal cancer. Biomed Rep. 2017;6(1):39–45. · DOI
  53. Yu W, et al. Circulating microRNA-21 as a potential diagnostic marker for colorectal cancer: a meta-analysis. Mol Clin Oncol. 2016;4(2):237–44. · DOI
  54. Yuan DW, et al. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol Ther. 2015;16(2):268–75. · DOI
  55. Zhi ML, et al. Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis. Genet Mol Res. 2015;14(4):18018–25. · DOI
  56. Ng EK, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375–81. · DOI · Paper page
  57. Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets. 2010;12(13):1925-56. Review. PubMed PMID: 21158707. · DOI
  58. Yang X, et al. MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2014;9(2):e88745. · DOI
  59. Wang J, et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One. 2014;9(4):e87451. · DOI
  60. Zhang Y, et al. Serum microRNA profile in patients with colon adenomas or cancer. BMC Med Genet. 2017;10(1):23.
  61. Giraldez MD, et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol. 2013;11(6):681–8 e3. · DOI
  62. Yuan T, et al. Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep. 2016;6:19413. · DOI
  63. Burch JA, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen. 2007;14(3):132–7. · DOI
  64. Wu CW, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61(5):739–45. · DOI · Paper page
  65. Yau TO, et al. MicroRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer. Oncotarget. 2016;7(2):1559–68. · DOI
  66. Yau TO, et al. microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer. 2014;111(9):1765–71. · DOI
  67. Kalimutho M, et al. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 2011;46(12):1391–402. · DOI
  68. Yamada A, et al. Serum miR-21, miR-29a, and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res. 2015;21(18):4234–42. · DOI
  69. Elshafei A, et al. The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: an Egyptian study. Tumour Biol. 2017;39(6):1010428317705765. · DOI
  70. Krawczyk P, et al. Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer. Int J Color Dis. 2017;32(7):1057–60. · DOI
  71. Chang PY, et al. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. Oncotarget. 2016;7(9):10663–75. · DOI
  72. Chen C, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179. · DOI
  73. Redshaw N, et al. A comparison of miRNA isolation and RT-qPCR technologies and their effects on quantification accuracy and repeatability. BioTechniques. 2013;54(3):155–64. · DOI
  74. Balcells I, Cirera S, Busk PK. Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers. BMC Biotechnol. 2011;11:70. · DOI
  75. Imaoka H, et al. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Ann Oncol. 2016;27(10):1879–86. · DOI
  76. Matsumura T, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015;113(2):275–81. · DOI · Paper page
  77. Phua LC, et al. Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians. Oncol Rep. 2014;32(1):97–104. · DOI
  78. Draghici S, et al. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet. 2006;22(2):101–9. · DOI · Paper page
  79. Sato F, et al. Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS One. 2009;4(5):e5540. · DOI
  80. Meyer SU, et al. Profound effect of profiling platform and normalization strategy on detection of differentially expressed microRNAs—a comparative study. PLoS One. 2012;7(6):e38946. · DOI
  81. Wu D, et al. The use of miRNA microarrays for the analysis of cancer samples with global miRNA decrease. RNA. 2013;19(7):876–88. · DOI · Paper page
  82. Pradervand S, et al. Impact of normalization on miRNA microarray expression profiling. RNA. 2009;15(3):493–501. · DOI
  83. Rao Y, et al. A comparison of normalization techniques for microRNA microarray data. Stat Appl Genet Mol Biol. 2008;7(1):Article22. · DOI
  84. Wang B, Xi Y. Challenges for microRNA microarray data analysis. Microarrays (Basel). 2013:2(2):34–50. · DOI
  85. Margulies M, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437(7057):376–80. · DOI · Paper page
  86. Shao K, et al. Emulsion PCR: a high efficient way of PCR amplification of random DNA libraries in aptamer selection. PLoS One. 2011;6(9):e24910. · DOI
  87. Ma Z, et al. Isothermal amplification method for next-generation sequencing. Proc Natl Acad Sci U S A. 2013;110(35):14320–3. · DOI
  88. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333–51. · DOI · Paper page
  89. Fuller CW, et al. The challenges of sequencing by synthesis. Nat Biotechnol. 2009;27(11):1013–23. · DOI
  90. Li J, et al. An NGS workflow blueprint for DNA sequencing data and its application in individualized molecular oncology. Cancer Inform. 2015;14(Suppl 5):87–107.
  91. Ansorge WJ. Next-generation DNA sequencing techniques. New Biotechnol. 2009;25(4):195–203. · DOI · Paper page
  92. Chatterjee A, et al. A cross comparison of technologies for the detection of microRNAs in clinical FFPE samples of hepatoblastoma patients. Sci Rep. 2015;5:10438. · DOI
  93. Malone JH, Oliver B. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol. 2011;9:34. · DOI
  94. Park ST, Kim J. Trends in next-generation sequencing and a new era for whole genome sequencing. Int Neurourol J. 2016;20:76–83. · DOI
  95. Vychytilova-Faltejskova P, et al. Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis. 2016;37(10):941–50. · DOI
  96. Ho GYF, et al. Differential expression of circulating microRNAs according to severity of colorectal neoplasia. Transl Res. 2015;166(3):225–32. · DOI
  97. Zheng G, et al. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br J Cancer. 2014;111(10):1985–92. · DOI
  98. Zhao Y, et al. Isothermal amplification of nucleic acids. Chem Rev. 2015;115(22):12491–545. · DOI
  99. Jia H, et al. Ultrasensitive detection of microRNAs by exponential isothermal amplification. Angew Chem Int Ed Engl. 2010;49(32):5498–501. · DOI
  100. Li C, et al. One-step ultrasensitive detection of microRNAs with loop-mediated isothermal amplification (LAMP). Chem Commun (Camb). 2011;47(9):2595–7. · DOI
  101. Jonstrup SP, Koch J, Kjems J. A microRNA detection system based on padlock probes and rolling circle amplification. RNA. 2006;12(9):1747–52. · DOI
  102. Tian Q, et al. Carbon nanotube enhanced label-free detection of microRNAs based on hairpin probe triggered solid-phase rolling-circle amplification. Nano. 2015;7(3):987–93.
  103. Li Y, Liang L, Zhang CY. Isothermally sensitive detection of serum circulating miRNAs for lung cancer diagnosis. Anal Chem. 2013;85(23):11174–9. · DOI
  104. Sun Y, et al. Rapid and direct microRNA quantification by an enzymatic luminescence assay. Anal Biochem. 2012;429(1):11–7. · DOI
  105. Ge J, et al. A highly sensitive target-primed rolling circle amplification (TPRCA) method for fluorescent in situ hybridization detection of microRNA in tumor cells. Anal Chem. 2014;86(3):1808–15. · DOI
  106. Yin BC, Liu YQ, Ye BC. One-step, multiplexed fluorescence detection of microRNAs based on duplex-specific nuclease signal amplification. J Am Chem Soc. 2012;134(11):5064–7. · DOI
  107. Pang Y, et al. Fe(3)O(4)@Ag magnetic nanoparticles for microRNA capture and duplex-specific nuclease signal amplification based SERS detection in cancer cells. Biosens Bioelectron. 2016;79:574–80. · DOI
  108. Wang Q, et al. Colorimetric detection of sequence-specific microRNA based on duplex-specific nuclease-assisted nanoparticle amplification. Analyst. 2015;140(18):6306–12. · DOI
  109. Shuai HL, et al. Au nanoparticles/hollow molybdenum disulfide microcubes based biosensor for microRNA-21 detection coupled with duplex-specific nuclease and enzyme signal amplification. Biosens Bioelectron. 2017;89(Pt 2):989–97. · DOI
  110. Dirks RM, Pierce NA. Triggered amplification by hybridization chain reaction. Proc Natl Acad Sci U S A. 2004;101(43):15275–8. · DOI
  111. Miao J, et al. A plasmonic colorimetric strategy for visual miRNA detection based on hybridization chain reaction. Sci Rep. 2016;6:32219. · DOI
  112. Miao X, et al. Sensitive detection of miRNA by using hybridization chain reaction coupled with positively charged gold nanoparticles. Sci Rep. 2016;6:32358. · DOI
  113. Ge Z, et al. Hybridization chain reaction amplification of microRNA detection with a tetrahedral DNA nanostructure-based electrochemical biosensor. Anal Chem. 2014;86(4):2124–30. · DOI
  114. Yang L, et al. Graphene surface-anchored fluorescence sensor for sensitive detection of microRNA coupled with enzyme-free signal amplification of hybridization chain reaction. ACS Appl Mater Interfaces. 2012;4(12):6450–3. · DOI
  115. Bi S, et al. Triggered and catalyzed self-assembly of hyperbranched DNA structures for logic operations and homogeneous CRET biosensing of microRNA. Chem Commun (Camb). 2016;52(31):5455–8. · DOI
  116. Cheglakov Z, et al. Live cell microRNA imaging using cascade hybridization reaction. J Am Chem Soc. 2015;137(19):6116–9. · DOI
  117. Cardoso J, et al. Genomic profiling by DNA amplification of laser capture microdissected tissues and array CGH. Nucleic Acids Res. 2004;32(19):e146. · DOI
  118. Hirsch D, et al. A new whole genome amplification method for studying clonal evolution patterns in malignant colorectal polyps. Genes Chromosomes Cancer. 2012;51(5):490–500. · DOI
  119. Aldecoa I, et al. Molecularly determined total tumour load in lymph nodes of stage I–II colon cancer patients correlates with high-risk factors. A multicentre prospective study. Virchows Arch. 2016;469(4):385–94. · DOI
  120. Rakislova N, et al. Lymph node pooling: a feasible and efficient method of lymph node molecular staging in colorectal carcinoma. J Transl Med. 2017;15(1):14. · DOI
  121. Persano S, et al. Label-free isothermal amplification assay for specific and highly sensitive colorimetric miRNA detection. ACS Omega. 2016;1(3):448–55. · DOI
  122. Zhou W, et al. RNA responsive and catalytic self-assembly of DNA nanostructures for highly sensitive fluorescence detection of microRNA from cancer cells. Chem Commun (Camb). 2015;51(92):16494–7. · DOI
  123. Kim E, et al. Multi-amplified sensing of microRNA by a small DNA fragment-driven enzymatic cascade reaction. ACS Sens. 2017;2(1):111–8. · DOI
  124. Feng C, et al. Detection of microRNA: a point-of-care testing method based on a pH-responsive and highly efficient isothermal amplification. Anal Chem. 2017;89(12):6631–6. · DOI
  125. Jiang HX, et al. G-quadruplex fluorescent probe-mediated real-time rolling circle amplification strategy for highly sensitive microRNA detection. Anal Chim Acta. 2016;943:114–22. · DOI
  126. Gong YJ, et al. A unique approach toward near-infrared fluorescent probes for bioimaging with remarkably enhanced contrast. Chem Sci. 2016;7(3):2275–85. · DOI
  127. Khreis OM, et al. 980 nm electroluminescence from ytterbium tris (8-hydroxyquinoline). Org Electron. 2001;2(1):45–51. · DOI
  128. Zhong Y, et al. BODIPY chromophores as efficient green light sensitizers for lanthanide-induced near-infrared emission. Dalton Trans. 2011;40:11389–95. · DOI
  129. Lincheneau C, et al. Recent highlights in the use of lanthanide-directed synthesis of novel supramolecular (luminescent) self-assembly structures such as coordination bundles, helicates and sensors. Aust J Chem. 2011;64(10):1315–26. · DOI
  130. Comby, S. and J.-C.G. Bünzli. Chapter 235 lanthanide near-infrared luminescence in molecular probes and devices. In: Handbook on the physics and chemistry of rare earths. J. Karl A. Gschneidner, J.-C.G. Bünzli, and V.K. Pecharsky, Editors. North Holland: Elsevier; 2007. p. 217–470. · DOI
  131. Karhunen U, et al. Homogeneous detection of avidin based on switchable lanthanide luminescence. Anal Chem. 2011;83(23):9011–6. · DOI
  132. Karhunen U, et al. Luminescence switching by hybridization-directed mixed lanthanide complex formation. Anal Chem. 2010;82(2):751–4. · DOI
  133. Saneyoshi H, Ito Y, Abe H. Long-lived luminogenic probe for detection of RNA in a crude solution of living bacterial cells. J Am Chem Soc. 2013;135(37):13632–5. · DOI
  134. Nonat AM, Quinn SJ, Gunnlaugsson T. Mixed f-d coordination complexes as dual visible- and near-infrared-emitting probes for targeting DNA. Inorg Chem. 2009;48(11):4646–8. · DOI
  135. Mardanya S, et al. Homo- and heterobimetallic ruthenium(II) and osmium(II) complexes based on a pyrene-biimidazolate spacer as efficient DNA-binding probes in the near-infrared domain. Inorg Chem. 2016;55(7):3475–89. · DOI
  136. Miao P, et al. Near-infrared Ag2S quantum dots-based DNA logic gate platform for miRNA diagnostics. Anal Chem. 2016;88(15):7567–73. · DOI
  137. Shah P, et al. In-solution multiplex miRNA detection using DNA-templated silver nanocluster probes. Analyst. 2014;139(9):2158–66. · DOI
  138. He, H., Near-infrared emitting lanthanide complexes of porphyrin and BODIPY dyes. Coord Chem Rev, 2014. 273-274(0): p. 87-99. · DOI
  139. He H, et al. Iodized BODIPY as a long wavelength light sensitizer for the near-infrared emission of ytterbium(III) ion. ChemCommun. 2012;48(13):1886–8.
  140. Shavaleev NM, et al. Surprisingly bright near-infrared luminescence and short radiative lifetimes of ytterbium in hetero-binuclear Yb-Na chelates. Inorg Chem. 2009;48(16):7937–46. · DOI
  141. Kazuki K, Hirotatsu K, Tetsuo N. Functional near-infrared fluorescent probes. Chem Asian J. 2008;3(3):506–15. · DOI
  142. Borisov SM, Wolfbeis OS. Optical biosensors. Chem Rev. 2008;108(2):423–61. · DOI
  143. Kobayashi H, et al. New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev. 2010;110(5):2620–40. · DOI
  144. Pansare VJ, et al. Review of long-wavelength optical and NIR imaging materials: contrast agents, fluorophores, and multifunctional nano carriers. Chem Mater. 2012;24(5):812–27. · DOI
  145. Hong GA, AL Dai H. Near-infrared fluorophores for biomedical imaging. Nat Biomed Eng. 2017;1(1):0010. · DOI

Cited by

Sorted by citations

See all 42

Metadata

Authors
Moody, L., He, H., Pan, Y.-X., & Chen, H.
Venue
Clinical Epigenetics
Publisher
Springer Science and Business Media LLC
Published
2017-10-24
Volume
9
Issue
1
ISSN
  • 1868-7075
  • 1868-7083
DOI
10.1186/s13148-017-0420-9
PMC
PMC5655825
Cited by
42
References
4
Language
en
Licence
Funders
National Science Foundation (CHE-1507871)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review